INTRODUCTION
The proto-oncogene c-myb encodes a transcription factor that is expressed predominantly in immature hematopoietic, epithelial and endothelial cells and in many tumor types 1, 2 and is downregulated as cells become more differentiated. 3 In hematopoietic progenitor cells, c-Myb has an important role in the control of cell proliferation, survival and differentiation; 4 in vitro, downregulation of c-Myb expression leads to decreased proliferation and colony formation of myeloid progenitors, 5 whereas loss of c-Myb, in vivo, is embryonically lethal due to failure of fetal hematopoiesis. 6 Conditional knockout of c-Myb expression in adult hematopoietic stem cells causes loss of self-renewal due to impaired proliferation and accelerated differentiation, 7 suggesting that c-Myb has an essential role also in bone marrow primitive hematopoiesis. Constitutive overexpression of c-Myb in myeloid and erythroid cell lines blocks differentiation and prevents maturation-associated growth arrest. 8, 9 Aberrant c-Myb expression has been detected in several malignancies including T-cell leukemia, 10 chronic myeloid leukemia (CML), acute myeloid leukemia, 11, 12 colorectal cancer, 13 breast cancer 14 and, more recently, adenoid cystic carcinomas. 15 In CML, the increased expression of c-Myb is, in part, due to enhanced protein stability via BCR/ABL-regulated activation of PI-3K/Akt/GSKIIIbdependent pathways; 16, 17 this altered regulatory mechanism may explain the requirement of c-Myb for in vitro proliferation and survival of leukemic progenitor cells 18, 19 and for leukemogenesis in mice. 20 Leukemic blast cells appear to rely on c-Myb expression more than their normal counterpart, 21 suggesting that this differential requirement for c-Myb may be exploited therapeutically.
The requirement of c-Myb may depend on its ability to modulate the expression of genes (that is, CD34, c-kit, c-myc, flt-3 and Bcl-2) with important roles for the proliferation and survival of hematopoietic cells. [22] [23] [24] [25] [26] c-Myb also regulates the expression of cyclin B1, contributing to the control of the G2/M phase of the cell cycle, in addition to its role during G1/S-phase transition.
the NRD domain. 34, 35 p89 c-Mybex9b represents 10-15% of total c-Myb protein in hematopoietic cells and has, apparently, the same properties of the predominant p75 c-Myb species: it localizes into the nucleus and binds to the same DNA-binding sequence. 36, 37 However, the 121 amino acids added by exon 9b could, in principle, enhance and/or modify the activity of the p89 c-Mybex9b isoform by disruption of the intra-and/or inter-molecular interactions that may regulate stability and transactivation activity of c-Myb. 38 The function and requirement of the p89 c-Mybex9b isoform is understood only in part: it appears to transactivate the expression of certain c-Myb targets more effectively than the predominant p75 c-Myb isoform, 39 and yet the specific knockout of p89 c-Mybex9b expression has no deleterious consequences on mammalian hematopoiesis and development, 40 suggesting that its loss is compensated by expression of p75 c-Myb . However, it is unknown whether expression of p89 c-Mybex9b is required for the proliferation and survival of transformed hematopoietic cells independently of p75 c-Myb expression. We show here that p89 c-Mybex9b is more stable and has higher transactivation activity than p75 c-Myb ; moreover, its specific downregulation impairs proliferation and colony formation and enhances the imatinib (IM) sensitivity of BCR/ABL-expressing cells, in spite of unperturbed expression of p75 c-Myb .
MATERIALS AND METHODS Plasmids
Mig-RI-c-Myb-HA and Mig-RI-D(358-452)c-Myb were obtained as described.
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Cyclin B1-Luc-pGL3 was a gift from the late Dr AM Gewirtz (University of Pennsylvania, Philadelphia, PA, USA). SLUG-Luc-pGL3 was recently described. fragments. They were digested with XhoI/AatII and AatII/EcoRI, respectively, and then ligated to XhoI/EcoRI-digested MSCV. MSCV-p89 c-Mybex9bMUT was generated by mutating four nucleotides of MSCV-p89 c-Mybex9b by two subsequent site-directed mutagenesis according to manufacturer's instructions (QuickChange II site-directed mutagenesis kit, Stratagene, Santa Clara, CA). Mutated primers were: 5 0 -CCACTGGTC ATCCTCCGGAAAAAACGGGGCCA-3 0 and its reverse complement (first mutagenesis); and 5 0 -CACAGCACAATTCCATTAGTCATCCTCCGGAAA-3 0 and its reverse complement (second mutagenesis).
Mig-RI-p89 c-Mybex9 plasmid was generated by digesting MSCV-p89
with XhoI/AatII and AatII/EcoRI and ligating the two fragments into XhoI/EcoRI-digested Mig-RI. MSCV-p89 , not inhibitable by the doxycycline (DOX)-regulated c-Myb-short hairpin RNA (shRNA)_pLVTSH lentivirus (gift of Dr TJ Gonda, Brisbane University, Australia), 41 were generated using the In-Fusion HD Cloning Kit (Clontech Laboratories, Mountain View, CA, USA). . Amplification products and linearized MSCV retroviral vector were ligated and cloned according to the kit's instructions. Correct mutations were confirmed by sequencing.
Cells and culture conditions
293T cells and parental and derivative K562 cell lines were maintained as described. 42 Peripheral blood (granulocyte colony-stimulating factor (G-CSF) mobilized) normal CD34 þ cells were purchased from Stem Cell Technologies (Stem Cell Technologies, Vancouver, British Columbia, Canada). CML chronic-phase fresh leukapheresis or peripheral blood samples were obtained with informed written consent from five patients. Samples were enriched for CD34 þ and cultured as described. 43 Transient transfection and dual-luciferase reporter assay
The Mig-RI D(358-452)c-Myb or p89 c-Mybex9 (3 mg) was co-transfected with cyclin B1-Luc-pGL3 or SLUG-Luc-pGL3 (1 mg) and Renilla luciferase (0.02 mg) into 10 6 K562 cells using nucleofector kit V (Amaxa; Lonza Group, Basel, Switzerland) according to the manufacturer's protocol. After 48 h, cells were diluted 1:5 in fresh medium and cultured for an additional 6-8 h. Cells were then lysed (100 ml of passive lysis buffer; Promega, Madison, WI, USA) and Firefly and Renilla luciferase activities were measured on a luminometer using the dual-luciferase reporter assay kit (Promega). For the assay in 293T cells, cells were seeded into six-well plates at 5 Â 10 4 cells per well. The following day, DNA (5 mg of reporter plasmid, 5 mg of effector plasmid and 0.5 mg of Renilla luciferase) was transfected using ProFection Mammalian Transfection System-Calcium Phosphate (Promega) following the manufacturer's protocol. Cells were washed 16 h after transfection and incubated in fresh medium for an additional 24 h. At 40 h post transfection, cells were lysed in 500 ml of passive lysis buffer per well (Promega) and Firefly and Renilla luciferase activities were measured as described. All the measurements were performed in triplicate.
Chromatin immunoprecipitation and co-immunoprecipitation -FLAG K562 cells, samples were prepared as described. 44 IPs were performed with anti-c-Myb antibody (30 mg; clone 1-1, Upstate Biotechnology, Millipore Corporation, Billerica, MA, USA) or anti-FLAG antibody (30 mg; clone M2, Sigma-Aldrich, St Louis, MO, USA) or anti-rabbit IgG or without antibody at 4 1C for 1 h with rotation. Immune complexes were collected with 45 ml of protein G-agarose beads at 4 1C overnight with rotation. Recovered DNA (2 ml) was used as a template for Real-Time PCR using GoTaq Real-Time PCR Mix (Promega) and primers on the 5 0 -flanking region of the human cyclin B1 27 or SLUG 28 promoter. Data were analyzed with the percent input method: percentage of input was calculated by 100 Â 2(Ct Input À Ct Enriched ).
For co-immunoprecipitations, 293T cells were transfected with plasmids expressing tagged c-Myb and lysates were immunoprecipitated with Anti-FLAG M2-Affinity gel (Sigma-Aldrich) following the manufacturer's instructions. Tagged proteins were detected by anti-FLAG M2-peroxidase-HRP (Sigma-Aldrich) and anti-HA-peroxidase High Affinity 3F10 (Roche, Nutley, NJ, USA).
Measurement of c-Myb half-life
To asses the half-life of p75 c-Myb and p89 c-Mybex9b
, cells (pre-treated or not with 2 mM IM for 16 h) were treated with cycloheximide (25 mg/ml) for 2 h to suppress protein synthesis. Samples were collected every 30 min and lysates (100 mg each) analyzed by anti-c-Myb western blotting. Later, bands corresponding to the c-Myb isoforms and to b-actin as loading control were scanned and densitometric analysis was carried out with ImageJ Software (National Institutes of Health). The half-lifes of p75 c-Myb and p89 c-Mybex9b were calculated using the formula: t 1/2 ¼ (0.693xt)/ln(Nt/No) as described. For induction of apoptosis, parental or derivative K562 cells were seeded at 2 Â 10 5 cells/ml and treated with 2 mM IM (1 mM added every 12 h) (LC Laboratories, Woburn, MA, USA). Cells were counted every 24 h by trypan blue exclusion and percentage of apoptosis evaluated by the hypotonic propidium iodide method 45 through Coulter Epics XL-MCL (Beckman Coulter Inc., Indianapolis, IN, USA).
G2/M-phase cells were also evaluated by propidium iodide staining. Phospho-histone-H3 positivity was assessed by Phospho-(Ser10)-histone-H3 (Cell Signalling Technology, Danvers, MA, USA) staining according to the manufacturer's instructions.
For colony-formation assays, K562 cells were plated in methylcellulose (Stem Cell Technologies) with or without IM (1 mM; pre-treatment in liquid culture for 24 h and added to the plates) and with or without doxycycline (5 mg/ml; pre-tratment in liquid culture for 24 h and added to the plates); colonies were counted 6 days later. CD34 þ cells were plated in methylcellulose supplemented with Cytokine Cocktail CC100 (Stem Cell Technologies) and colonies were counted 9 days later.
Statistical analyses
Data (presented as the means ± s.d. of two or three experiments) were analyzed for statistical significance by the unpaired, two-tailed Student's t-test. P-values of o0.05 were considered statistically significant. In addition to the transactivation ability, we also tested the stability of p89 c-Mybex9b because the insertion of ex9b disrupts the LZ domain and c-Myb LZ-domain mutant proteins are more stable than wild-type p75 c-Myb . 17 Thus, parental and p89 c-Mybex9b -expressing K562 cells were treated with cycloheximide for different times and cell lysates blotted with an anti-c-Myb antibody to assess half-life of endogenous p75 c-Myb and ectopic p89 c-Mybex9b , expressed at comparable levels. Expression of p75 c-Myb was more rapidly downmodulated of p89 ; by densitometry analysis, the half-life of p89 c-Mybex9b is B90 min, nearly 30 min longer than that of p75 c-Myb (Figures 3a and b) . Because p210 BCR/ABL enhances the stability of c-Myb, 17 we also assessed the half-life of the two c-Myb isoforms in IM-treated cells. -specific siRNAs proliferated less than control siRNA-transfected cells ( Figure 4c) ; at 48 h, the c-Myb siRNA pool was more effective than the p89 c-Mybex9b -specific siRNAs (54% versus 30% inhibition, respectively), but at 72 h, the effects were comparable.
RESULTS

Increased transactivation of c-
We also assessed the effect of p89 c-Mybex9b
-specific downregulation on colony formation of K562 cells. Thus, cells were transfected with control or specific siRNAs and 24 h after the second transfection were plated in methylcellulose (500 cells per plate) and colonies were counted 6 days later. Cells treated with control siRNA formed 350 ± 36 colonies (Figure 4d) , whereas K562 cells transfected with the c-Myb siRNA pool formed 178±27 colonies; a significant decrease in colony formation was also noted by plating cells transfected with p89 c-Mybex9b -siRNA-2 (230 ± 14 colonies) or p89 c-Mybex9b -siRNA-1 (230±11) (Figure 4d ). To assess the specificity of the biological effects induced by p89 c-Mybex9b
-siRNA-2, we generated K562-derivative lines ) K562 cells may be caused by changes in the expression of c-Myb-regulated genes with a role in cell proliferation. Cyclin B1, a gene with an essential role in the G2/M transition, is one of the c-Myb targets 27 whose change in expression may explain, in part, the effects of p89 c-Mybex9b downregulation. Indeed, compared with control siRNA-transfected cells, cyclin B1 expression was reduced in K562 cells transfected with the c-Myb siRNA pool (B45% decrease of cyclin B1 levels); although expression of p75 c-Myb was unaffected, the specific downregulation of p89 c-Mybex9 led to a similar decrease (B42%) of cyclin B1 expression (Figures 5a and b) . c-Mybex9b -specific siRNA but the differences were not significant (Figure 6d) .
We also assessed the relationship between levels of p89 c-Mybex9b
and colony formation after IM treatment. Thus, parental or c-Mybex9b -siRNA was similar (1.1% and 1.9%, respectively) and lower of that from cells transfected with control siRNAs (3.1%) (Figure 6f ). Together, these data suggest that expression of the p89 c-Mybex9b isoform can modulate the effects of IM in K562 cells.
Inhibition of p89
c-Mybex9b suppresses colony formation of normal and CML CD34 þ progenitors
The role of p89 c-Mybex9b expression was also assessed in colony-formation assays of CD34 þ cells from healthy donors and CML patients.
Normal human CD34 þ cells (n ¼ 3) were transfected with the c-Myb siRNA pool or a p89 c-Mybex9b -specific siRNA or the control siRNA. 24 h after transfection, levels of c-Myb proteins were tested and cells were plated for colony-formation assays. A representative western blot shows that levels of p75 c-Myb and p89 c-Mybex9b -siRNA were fewer (63% and 41% decrease, respectively; range: 50-90% and 28-58% , respectively) than those from the scramble siRNA-transfected counterpart (Figure 7d) .
Together, these results suggest that expression of p89 c-Mybex9b
is more important for colony formation of CML than normal CD34 þ progenitors.
DISCUSSION
The c-Myb gene generates multiple transcripts that encode the predominant p75 c-Myb isoform and, potentially, several lessabundant species. 46 However, only the p89 c-Mybex9b isoform is readily detectable in hematopoietic cells, suggesting that other alternatively spliced transcripts are too rare to generate detectable proteins or that the encoded gene products are unstable and rapidly degraded. p89 c-Mybex9b accounts for 10-15% of total c-Myb protein, an amount that could be biologically relevant because c-Mybex9b isoform-specific knockout mice have no apparent defect in the number of steady-state mature hematopoietic cells, 40 but the long-term proliferative potential, survival and differentiation of specific progenitor subsets was not investigated in detail. Although this study suggests that, in normal cells, loss of p89 c-Mybex9b expression is compensated by expression of the more abundant p75 c-Myb isoform, it is conceivable that expression of p89 c-Mybex9b is biologically more relevant in leukemic cells, which typically rely on c-Myb expression more than their normal counterparts. 18, 21 We show here that perturbation of p89 c-Mybex9b levels by ectopic expression or by specific downregulation modulates the proliferation, survival and IM sensitivity of BCR/ABL-transformed cells. The increased proliferation, survival and IM resistance of p89 c-Mybex9b ectopically expressing K562 cells is reminiscent of similar effects observed in experiments carried out with artificial degradation-resistant mutants of the c-Myb LZ-NRD. 17 The similarity of the effects is likely to reflect the comparable increase in protein stability and transactivation ability of the artificial c-Myb mutants and the p89 c-Mybex9b isoform. Of greater interest, downregulation of the p89 c-Mybex9b isoform was associated with reduced proliferation and colony formation and with enhanced IM sensitivity of BCR/ABL-transformed cells comparable to that observed after transfection with the c-Myb siRNA pool, which caused the downregulation of both the predominant p75 c-Myb isoform and the less-abundant p89 c-Mybex9b species. An explanation for these surprising findings could be that downregulation of p89 c-Mybex9b expression suppresses an autoregulatory loop, which may maintain elevated levels of the p75 c-Myb isoform. 49 However, this putative mechanism does not appear to be involved because p75 c-Myb levels were not reduced in p89
c-Mybex9b -silenced cells. Another possibility is that disruption of the LZ-NRD in the p89 c-Mybex9b isoform prevents protein-protein interactions with p75 c-Myb or p75 c-Myb -interacting proteins, allowing p89 c-Mybex9b to escape the negative regulation imposed by p75 c-Myb and/or its interacting proteins. 50, 51 Consistent with this interpretation, co-immunoprecipitation assays showed that p75 c-Myb interacted with p89 c-Mybex9b less efficiently than it did with itself ( Supplementary Figure 3) . Thus, the biological effects of c-Myb in p210BCR/ABLtransformed cells might be exerted, to a large extent, by the less-abundant but more potent p89 c-Mybex9b isoform. The fact that p89 c-Mybex9b is a more potent transactivator of p75 c-Myb and downregulation of p89 c-Mybex9b is almost as effective as the combined downregulation of p75 c-Myb and p89
c-Mybex9b
in inducing a decrease in the expression of the c-Myb-target cyclin B1 supports this interpretation, although the entire catalogue of c-Myb-target genes should be examined. Lastly, the preferential requirement of the p89 c-Mybex9b isoform by BCR/ABL-transformed cells may depend on the regulation of a specific gene subset, which may be distinct from that regulated by p75 c-Myb . 39 This possibility is supported by the observation that restoring the expression of either the p75 c-Myb or p89
c-Mybex9b isoform rescued only in part the inhibition of colony formation induced by downregulation of both, consistent with nonoverlapping effects of the two isoforms. Regardless of the mechanisms involved, the observation that the effects of c-Myb in leukemic cells are, in a significant part, due to minute amounts of an alternatively spliced isoform raises new questions regarding the elusive oncogenic potential of c-Myb.
